VA-REGULA
23.4.2024 09:01:33 CEST | Business Wire | Press release
In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the results of a global survey conducted by Regula, a global developer of forensic devices and identity verification solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423489077/en/
Top problems businesses deal with when verifying foreign IDs, according to Regula’s survey (Graphic: Business Wire)
Key challenges for businesses
When it comes to identity verification for international customers, including a growing community of digital nomads, organizations from various industries participating in Regula’s survey tend to point out the following challenges:
- The lack of unified document standards. 41% of decision-makers in all sectors report a significant challenge due to the lack of standardized identity documents. This inconsistency affects the efficiency and speed of IDV processes. For government services, the problem seems to be even worse, since 48% of the respondents in this sphere named this issue as the main challenge.
- The increase in fraud. Identity-related fraud continues to be a major concern, affecting 40% of businesses overall. Higher impacts of fraud are observed in Banking and Financial Services (48% of respondents call it a key challenge) and Retail (44% of respondents).
- Language barriers. Complexities due to language differences are reported by 36% of businesses. For the Healthcare and Insurance industries, this is an even greater concern, with 41% and 39% of respondents correspondingly naming it among the top three challenges.
Dealing with new identity documents and facing new risks, organizations strive to pursue a high level of identity verification (IDV) security and accuracy, with every third of them expressing the need for an increase in their IDV budget by up to 20%.
"As the world is starting to pilot the concept of digital IDs, it is possible that in the foreseeable future, we will achieve a certain level of identity document standardization. That means some of the current challenges in international ID verification will likely be mitigated,” says Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula. “In the meantime, both businesses and IDV providers have to concentrate on tackling fraud and language barriers. From our experience, we see that there are two effective ways of dealing with these issues: enhancing the set of document and biometric checks, with a strong emphasis on data cross-checks to spot any possible inconsistencies that may indicate fraud, and growing your own document knowledge database to be able to read any document in any language correctly.”
Major concerns for customers
In their turn, digital nomads who settle in foreign countries for short or long periods of time also face challenges related to identity verification. Predominantly, their concerns revolve around the document validity period, which has an expiry date and proof of residency, such as rental agreements or utility bills. Each of these issues is a challenge for 19% of Regula’s survey respondents.
Apart from that, 18% of digital nomads have difficulties with ID verification because of their frequent travel and changing locations, which create inconsistencies in the information provided, and potentially lead to delays or rejection in identity proofing. Another 18% of respondents feel a lack of trust and credibility from institutions due to the unconventional nature of their lifestyle and work arrangements.
As for the language barrier, 70% of digital nomads say they have encountered language difficulties in understanding the instructions during the verification process. However, only 16% of nomads cite language barriers as a top frustration during the ID verification process. At the same time, twice as many digital nomads (36%) feel frustrated because of Internet connectivity issues: majorly relying on public Wi-Fi networks, they face an increased risk of cybersecurity threats and data breaches during the verification process.
The research has also shown that only 29% of nomads are very comfortable with providing sensitive identification documents online while being in a foreign country.
To learn more about the concerns and frustrations for both businesses and digital nomads, read the full report on the survey. To find out how to cope with various difficulties during the identity verification process, please visit Regula’s solutions page and learn about the advanced technologies for document and biometric checks.
*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.
Resources:
- Blog article Identity Verification in a Globalized World -– https://regulaforensics.com/blog/identity-verification-in-nomad-era-research/
- Survey report Identity Verification in a Globalized World – https://regulaforensics.com/resources/identity-verification-for-digital-nomads-report/
- Regula Document Reader SDK – https://regulaforensics.com/products/document-reader-sdk/
- Regula Face SDK – https://regulaforensics.com/products/face-recognition-sdk/
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423489077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
